Key points are not available for this paper at this time.
Minimal residual disease (MRD) monitoring for mutated NPM1 is increasingly used to guide treatment decisions in patients with acute myeloid leukemia (AML) carrying this mutation. NPM1-MRD positivity after induction was shown to identify patients who benefit from allogeneic hematopoietic cell transplantation (alloHCT), and NPM1-MRD monitoring after alloHCT can detect early relapse enabling the prompt initiation of salvage therapy. However, recommendations for clinical decision making based on peri-transplant NPM1-MRD levels are missing. In this study, we retrospectively analyze 172 patients with NPM1-mutant AML treated at two German centers to explore the predictive values of NPM1-MRD measured pre- and post-alloHCT. We found that pre-transplant MRD negativity was a strong predictor of favorable long-term overall survival (OS). In contrast, patients with positive and negative NPM1-MRD status at day 30 post-HCT showed comparable OS. Finally, statistically derived NPM1-MRD thresholds effectively stratified MRD-high and MRD-low patient groups with differential outcome with two peri-transplant MRD risk scores obtained by longitudinal integration. Firstly, a combined pre-HCT/+d30 post-HCT score to guide early reduction of immunosuppression (C-index, 0.737), and secondly, a combined pre-HCT+d30+d100 score to guide later interventions post-HCT (C-index, 0.841; stratified 2-year OS groups 100%, 90.1%, 57.1% and 25.7%; p0.0001). This approach predicted OS better than age, FLT3-ITD status, or morphological remission status. We propose that in the peri-transplant setting, NPM1-MRD thresholds are superior to conventional MRD analysis based on binary or log-step change data.
Schroeder et al. (Tue,) studied this question.